Preclinical Triple-Humanized genO-hVISTA/hFcRn/hFcγR Mouse Model

genO‑hCD137 immunocompetent mice enable the in vivo efficacy assessment of anti-CD137.

‍

The genO‑hCD28 mouse enables the in vivo efficacy and safety assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD28 in fully immunocompetent mice.

Triple-humanized genO-hCD28/hPD-1/hPD-L1 immunocompetent mice enable the in vivo efficacy and safety assessment of anti-CD28 and PD-1/PD-L1 compounds.

The genO‑hCD39 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD39 in fully immunocompetent mice.

Double-humanized genO‑hCD47/hSIRPα immunocompetent mice enable the in vivo efficacy and safety assessment of anti-CD47/SIRPα.

‍

Triple-humanized genO‑hCD47/hSIRPα/hFcγR immunocompetent mice enable the in vivo efficacy and safety assessment of anti-CD47/SIRPα antibodies with a competent or engineered Fc region.

‍

The genO‑hcGAS/hSTING mouse enables the in vivo efficacy assessment of compounds targeting the human cGAS-STING pathway in fully immunocompetent mice.

The genO‑hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 in fully immunocompetent mice.

The genO‑hCTLA-4/hLAG3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 and/or LAG3 in fully immunocompetent mice.

Preclinical humanized Fc-gamma receptor (genO‑hFcγR) model enabling the in vivo assessment of Fc receptor-targeted therapies.

‍

Double-humanized genO‑hFcγR/hFcRn mouse model to improve PK and efficacy assessment of compounds with extended half-life through FcRn binders.

‍

Double-humanized genO-hFcγR/hIgG1 mouse model to improve the tolerability to human IgG1 therapeutic antibodies.

‍

The genO‑hGITR mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR in fully immunocompetent mice.

The genO‑hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of agonist and antagonist antibodies targeting human immune checkpoint GITR and/or GITRL in fully immunocompetent mice.

The genO-hICOS mouse enables the in vivo efficacy assessment of anti-ICOS-targeting agents in fully immunocompetent mice.

Use the genO‑hIgE/hFcεR1 mouse model to successfully screen for innovative therapeutics for allergy, asthma and other IgE-mediated diseases.

The genO-hOX40 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint OX40 in fully immunocompetent mice.

The genO‑hOX40/hICOS mouse enables the in vivo efficacy assessment of compounds targeting the human immune checkpoint OX40 and/or ICOS in fully immunocompetent mice.

The genO‑hPD‑1 mouse enables the in vivo efficacy assessment and profiling of compounds targeting the human immune checkpoint PD-1 in fully immunocompetent mice

The genO‑hPD-1/hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or CTLA-4 in fully immunocompetent mice.

Double-humanized genO-hPD-1/hFcγR immunocompetent mice enable the in vivo efficacy and safety assessment of anti-PD-1 antibodies with a competent or engineered Fc region.

The genO-hPD-1/hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1, GITR and/or GITRL in fully immunocompetent mice.

The genO‑hPD‑1/hICOS mouse enables the in vivo efficacy assessment of compounds targeting the human immune checkpoint PD-1 and/or ICOS in fully immunocompetent mice.

The genO‑hPD‑1/hLAG3 mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1 and/or LAG3 in fully immunocompetent mice.

The genO‑hPD-1/hPD-L1 mouse model enables in vivo efficacy assessment and profiling of molecules targeting the human PD-1/PD-L1 axis in fully immunocompetent mice.

The genO‑hPD‑1/hTIM3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or TIM3 in fully immunocompetent mice.

The genO‑hPD‑1/hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or VISTA in fully immunocompetent mice.

Double-humanized genO‑hSA/hFcRn mouse model as a cutting-edge platform for preclinical development of hSA (hALB) and FcRn-oriented therapeutics.

This upgraded, immunocompromised RAG1^-/- version of our genO-hSA/hFcRn mouse model allows the assessment of compounds' half-life and anti-tumor efficacy in a human tumor model.

Double-humanized genO-hTFRC/hFcγR mouse model to improve biodistribution and enable drug shuttling through the blood-brain barrier (BBB) by binding to human human TFRC (CD71, TfR1).

‍

Triple-humanized genO-hTFRC/hSA/hFcRn mouse model for PK assessment of drugs aiming to cross the blood-brain barrier (BBB) by binding to human human TFRC (CD71, TfR1).

‍

The genO-hTIGIT mouse enables the in vivo efficacy assessment of TIGIT-targeting agents in fully immunocompetent mice.

The genO‑hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint VISTA in fully immunocompetent mice.

Double-humanized genO-hVISTA/hFcγR immunocompetent mice enable the in vivo efficacy and safety assessment of anti-VISTA antibodies with a competent or engineered Fc region.

Double-humanized genO-panhCD3/hCD137 immunocompetent mice enable the in vivo efficacy and safety assessment of anti-CD3 and CD137 compounds.

Double-humanized genO-panhCD3/hCD28 immunocompetent mice enable the in vivo efficacy and safety assessment of anti-CD3 and CD28 compounds.

‍

Double-humanized genO-panhCD3/hPD-1 immunocompetent mice enable the in vivo efficacy and safety assessment of anti-CD3 and PD-1 compounds.

The genO-CT26-hCD39-LZ clonal cell line expresses high levels of human/mouse chimeric CD39, and forms solid tumors in vivo.

The genO-CT26-hCD47-LZ clonal cell line expresses human CD47, an optimized dual fusion reporter, luciferase-ZsGreen (LZ) and forms solid tumors in vivo.

genO-CT26-hEpCAM-LZ clonal cell line expresses high levels of human EpCAM, and forms solid tumors in vivo.

The humanized hPD-L1 syngeneic clonal colon carcinoma CT26 cell line expresses high levels of human PD-L1 and forms solid tumors in vivo.

The Pd-l1 Knockout colon carcinoma CT26 cell line is invalidated for murine Pd-l1 and can be used for target validation and mechanistic studies.

genO-EL4-hCD19-LZ cells form tumors in syngeneic models, upon subcutaneous and systemic (i.v.) injection, in immunocompetent mice.

The genO-EL4-hCD20-LZ clonal cell line expresses high levels of human CD20.

The genO-MC38-hCD39-LZ cells homogeneously express human CD39 in vitro, and form infiltrated tumors in immunocompetent mice.

The genO-MC38-hEpCAM-LZ clonal cell line expresses human EpCAM (NCBI GeneID: 4072), and an optimized dual fusion reporter, luciferase-ZsGreen (LZ)

The genO‑MC38-hPD-L1-hCD47-LZ clonal cell line expresses high levels of human PD-L1 and human CD47.

The genO-MC38-hPD-L1-hFAP-LZ clonal cell line expresses human PD-L1, human FAP and an optimized dual fusion reporter, luciferase-ZsGreen (LZ)

The genO-MC38-hPD-L1-hHER2-LZ clonal cell line expresses high levels of human PD-L1  and human HER2.

The genO-MC38-hPD-L1-LZ clonal cell line expresses high levels of  human PD-L1 and forms solid tumors in vivo. An optimized version of a  luciferase-ZsGreen (LZ) fusion protein is also stably expressed for in vivo imaging and ex vivo tracking.

The Pd-l1 Knockout colon adenocarcinoma MC38 cell line is invalidated for murine Pd-l1 and can be used for target validation and mechanistic studies.